Search by Drug Name or NDC

    NDC 63824-0112-08 Delsym 650; 20; 400; 10 mg/1; mg/1; mg/1; mg/1 Details

    Delsym 650; 20; 400; 10 mg/1; mg/1; mg/1; mg/1

    Delsym is a ORAL POWDER, FOR SOLUTION in the HUMAN OTC DRUG category. It is labeled and distributed by RB Health (US) LLC. The primary component is ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE.

    Product Information

    NDC 63824-0112
    Product ID 63824-112_dc5c49d8-9fdb-4d72-a6dd-cb54a3716cf0
    Associated GPIs
    GCN Sequence Number n/a
    GCN Sequence Number Description n/a
    HIC3 n/a
    HIC3 Description n/a
    GCN n/a
    HICL Sequence Number n/a
    HICL Sequence Number Description n/a
    Brand/Generic n/a
    Proprietary Name Delsym
    Proprietary Name Suffix Cough Plus Cold Day Time
    Non-Proprietary Name acetaminophen, dextromethorphan hydrobromide, guaifenesin, and phenylephrine hydrochloride
    Product Type HUMAN OTC DRUG
    Dosage Form POWDER, FOR SOLUTION
    Route ORAL
    Active Ingredient Strength 650; 20; 400; 10
    Active Ingredient Units mg/1; mg/1; mg/1; mg/1
    Substance Name ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE
    Labeler Name RB Health (US) LLC
    Pharmaceutical Class Adrenergic alpha1-Agonists [MoA], Decreased Respiratory Secretion Viscosity [PE], Expectorant [EPC], Increased Respiratory Secretions [PE], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC
    DEA Schedule n/a
    Marketing Category OTC MONOGRAPH FINAL
    Application Number part341
    Listing Certified Through 2023-12-31

    Package

    NDC 63824-0112-08 (63824011208)

    NDC Package Code 63824-112-08
    Billing NDC 63824011208
    Package 8 POWDER, FOR SOLUTION in 1 CARTON (63824-112-08)
    Marketing Start Date 2014-04-01
    NDC Exclude Flag N
    Pricing Information N/A

    Standard Product Labeling (SPL)/Prescribing Information SPL ce07952b-4a0f-4d72-b7f9-c032f89ec1f5 Details

    Revised: 1/2022